NABRIVA THERAPEUTICS AG (NASDAQ:NBRV) Files An 8-K Other Events

ME Staff 8-k

7 years ago

NABRIVA THERAPEUTICS AG (NASDAQ:NBRV) Files An 8-K Other EventsItem 8.01 Other Information.

On June 8, 2017, in connection with the previously announced tender offer (the “Exchange Offer”) related to the exchange of American depositary shares (“Nabriva AG ADSs”) and common shares (“Nabriva AG Common Shares”) of Nabriva Therapeutics AG for ordinary shares of Nabriva Therapeutics plc (“Nabriva Ireland”), Nabriva Ireland distributed a communication to certain holders of Nabriva AG ADSs to remind such holders of the Exchange Offer and to provide information regarding how to tender into the Exchange Offer. The communication is attached hereto as Exhibit 99.1.

The information in this Form 8-K, including Exhibit 99.1, shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such a filing.

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits

See Exhibit Index attached hereto.

About NABRIVA THERAPEUTICS AG (NASDAQ:NBRV)
Nabriva Therapeutics AG is an Austria-based clinical-stage biopharmaceutical company engaged in the research and development of antibiotics to treat infections. Its product pipeline includes lefamulin, a Phase Three plueromutilin antibiotic in intravenous (IV) and oral formulations for the treatment of community-acquired bacterial pneumonia (CABP), and BC-7013, a Phase One topical pleuromutilin treatment for Gram-positive infections, including uncomplicated skin and skin structure infections (uSSSSIs). In addition, the Company has completed a Phase Two clinical trial for acute bacterial skin and skin structure infections (ABSSSI) and Discovery Phase development of extended-spectrum pleuromutilins (ESPs), a pleuromutilin compound that treats Gram-negative bacteria. The Company is a spin-off of Sandoz GmbH.